Several pathological biomarkers cannot be easily detected by current techniques because of their low concentration in biological fluids, the presence of degrading enzymes, and large amounts of high molecular weight proteins. Chemically functionalized hydrogel nanoparticles can harvest, preserve and concentrate low abundance proteins enabling the detection of previously undetectable biomarkers.
Novel biomarker discovery plays a crucial role in providing more sensitive and specific disease detection. Unfortunately many low-abundance biomarkers that exist in biological fluids cannot be easily detected with mass spectrometry or immunoassays because they are present in very low concentration, are labile, and are often masked by high-abundance proteins such as albumin or immunoglobulin. Bait containing poly(N-isopropylacrylamide) (NIPAm) based nanoparticles are able to overcome these physiological barriers. In one step they are able to capture, concentrate and preserve biomarkers from body fluids. Low-molecular weight analytes enter the core of the nanoparticle and are captured by different organic chemical dyes, which act as high affinity protein baits. The nanoparticles are able to concentrate the proteins of interest by several orders of magnitude. This concentration factor is sufficient to increase the protein level such that the proteins are within the detection limit of current mass spectrometers, western blotting, and immunoassays. Nanoparticles can be incubated with a plethora of biological fluids and they are able to greatly enrich the concentration of low-molecular weight proteins and peptides while excluding albumin and other high-molecular weight proteins. Our data show that a 10,000 fold amplification in the concentration of a particular analyte can be achieved, enabling mass spectrometry and immunoassays to detect previously undetectable biomarkers.
Despite the completion of the human genome sequencing, significant progress has not been made in identifying biomarkers predictive of early stage disease, or that correlate with therapeutic outcome, or prognosis1. One reason for this lack of progress is that many potentially significant biomarkers exist at a concentration below the detection limit of conventional mass spectrometry and other biomarker discovery platforms. Mass spectrometry (MS) and Multiple Reaction Monitoring (MRM) have a detection sensitivity typically greater than 50 ng/ml while the majority of the analytes measured by immunoassays in a clinical laboratory fall in the range between 50 pg/ml and 10 ng/ml. This means that many biomarkers, particularly in the early stage of a disease cannot be detected by conventional MS and MRM2. In addition the presence of high-abundance proteins such as albumin and immunoglobulin in complex biological fluids often mask by billion-fold excess low-abundance, low molecular weight proteins and peptides3, 4. For this reason several sample preparatory steps are required prior to mass spectrometry sequencing and identification. One such preparatory step employs the depletion of high-abundance proteins with commercially available depletion columns5-8. Unfortunately this step leads to the reduction of the yield of candidate biomarkers because they are often non-covalently associated with carrier proteins that are being removed. Another challenge is represented by the stability of candidate biomarkers ex-vivo once the samples are collected. Proteins are subject to degradation by endogenous or exogenous proteases9. Hydrogel nanoparticles can transcend these critical challenges by amplifying the putative biomarker concentration to a level within the range of the assay, while protecting the protein from degradation10-13.
It’s important to note that LMW proteins in blood are a mixture of small intact proteins as well as fragments of large proteins. Tissue-derived proteins larger than 60 kDa are too large to passively enter the blood stream through the vascular basement membrane, but they can be represented in blood as peptides or protein fragments14. Our goal is to measure novel circulating biomarkers that can be candidates for early detection of disease, patient stratification for therapy, and monitoring the response to therapy. Our nanoparticles are created to selectively exclude high abundance immunoglobulins and albumin, while simultaneously capturing smaller proteins and peptides and concentrating them up to 100-fold depending on the starting volume.
Our group identified a set of small organic dyes which can successfully act as high affinity molecular baits for proteins and peptides. Protein-dye binding is thought to be due to a combination of hydrophobic and electrostatic interactions. The aromatic rings on the dye interleave with proteins via hydrophobic pockets on the protein surface11.
The baits, depending on their chemistry, show a particular affinity for selected classes of analytes. The baits compete with the carrier proteins, such as albumin, for the proteins or peptides. The low-molecular weight proteins/peptides become trapped in the particle. High-molecular weight proteins such as albumin and immunoglobulin are prevented from entering the particle because of the sieving capability due to the restrictive pore of the hydrogel11(Figure 1).
Hydrogel nanoparticles are synthesized by precipitation polymerization initiated by ammonium persulfate11. N-isopropylacrylamide (NIPAm), co-monomers of acrylic acid (AAc) and allylamine (AA) and cross-linker N,N’-Methylenebisacrylamide (BIS) are allowed to react at 70 °C for 6 hr in dilute conditions11, 13. The high protein binding affinity of poly(N-isopropylacrylamide-co-acrylic acid) (poly(NIPAm-co-AAc) nanoparticlesis achieved by covalently incorporating amino-containing dyes (i.e., sulfonatedanthraquinonetriazine dyes) into the nanoparticles through an amidation reaction performed in aqueous or organic solvents depending on the hydrophilic/hydrophobic characteristics of the dyes11, 13. Nucleophilic substitution of the amine groups in the nanoparticle with the chloride atom of an anthraquinonetriazine dye is utilized to create dye-containing poly(NIPAm-co-Allylamine) (AA) nanoparticles11, 12. A two-step polymerization process is utilized to create hydrogel nanoparticles containing an outer shell of vinylsulfonic acid (VSA)11, 13.
Hydrogel nanoparticles can be applied to various biological fluids, including whole blood, plasma, serum, cerebrospinal fluid, sweat, and urine. In one step, in solution, the nanoparticles perform a rapid (within minutes) sequestration and concentration of low molecular weight analytes10, 11, 13, 15-18. Proteins are subsequently eluted from the nanoparticles and detected using western blotting19-21, mass spectrometry10, 11, 13, 15, 18, 22, 23, immunoassays/ELISA10, 11, 15, 18, or reverse phase protein microarray16, 24 assays. Nanoparticles functionalized with chemical bait, and presenting a core or core shell architecture, capture and concentrate proteins based on the bait/shell physicochemical properties. Different dyes incorporated into the nanoparticles will therefore capture different subsets of proteins with varying efficiency based on the dye affinity, pH of the solution, and the presence/absence of competing high-abundant proteins13. Furthermore, the quantity of nanoparticles in relation to the volume of the solution will affect the protein yield from the nanoparticles. These aspects of hydrogel nanoparticle harvesting are demonstrated using three different nanoparticle baits for harvesting proteins from plasma samples which contain high amounts of protein, and from urine samples which typically do not contain large amounts of protein. In this protocol we demonstrate harvesting and concentrating tumor necrosis factor alpha (TNFα) from plasma samples using poly(NIPAm-co-AAc), Poly(NIPAm/dye), and core- shell nanoparticles (Poly(NIPAm-co-VSA)). Poly(NIPAm/dye) nanoparticles are shown to concentrate Mycobacterium species antigen that was added to human urine samples, to mimic Mycobacterium tuberculosis infected individuals.
Human plasma and urine was collected from healthy volunteer donors, with written informed consent, following George Mason University Institutional Review Board approved protocols. Donors were equally distributed between Caucasian males and females between the ages of 25 and 42. Samples were analyzed individually and were not pooled.
1. Nanoparticle Processing of Serum or Plasma Samples
Potential low abundant biomarkers in plasma are captured, in solution, with hydrogel nanoparticles. The particles are added to the plasma, incubated, separated by centrifugation, washed, and the captured proteins are eluted. The eluted proteins are dried under nitrogen flow for downstream mass spectrometry sequencing and identification.
2. Nanoparticle Processing of Urine Samples
Normal urine contains less than 30 mg/dl protein and less than 1+ blood. However, many diseases/conditions may alter the normal levels of urine protein and blood. To aid in determining the optimal volume of nanoparticles to add to the urine sample, a urinalysis is performed prior to nanoparticle harvesting. Urine biomarkers may exist in extremely low concentrations, which may require optimizing the ratio of nanoparticles to urine volume. This procedure describes nanoparticle harvesting of urine samples for downstream western blot analysis.
Hydrogel Nanoparticle Size and Uniformity
Poly(NIPAm-AAc) particles have been produced with extremely high yield and reproducibility between and within batches. The particles have very good colloidal stability at RT during the time required for capture, storage, and elution of proteins (at least 48 hr), and nanoparticle precipitation has not been observed (Figure 1)11. The colloidal stability may be very important for rapid protein/peptide uptake by the nanoparticles.
Potential Low-abundance Biomarkers Harvested from Plasma
The incorporation of the dye bait drives the uptake of molecules in solution and assures that captured molecules are preserved from degradation13, 15, 18, 25. For this reason, protease inhibitors are not needed during sample pre-processing. This attribute of the nanoparticles makes them suitable as a preservation technology for sample collection in the field and for shipment of biological fluids at RT.
The bait molecule can be incorporated in the hydrogel particle by copolymerization or covalent binding to functional groups present in the nanoparticle. As an example, poly(NIPAm-co-AAc) nanoparticles were constructed with amino containing dyes via zero length crosslinking amidation reactions, while nanoparticles with an outer shell containing vinylsulfonic acid (VSA) copolymer were created by a second polymerization reaction10-13. Different types of nanoparticles can be produced by incorporating a different chemical dye within the nanoparticle and thus enhance harvesting of specific classes of proteins. An important concept of our technology is that different baits can show a preferential affinity for different proteins because the dye-protein interaction is dependent mainly on a combination of hydrophobic interactions, 3-D interactions, and electrostatic forces. We have observed that some analytes can be captured with a high affinity by chemically different dyes because of the complexity of the binding forces. See Tamburro et al. for an extensive explanation and examples of this principle13. For example, four different types of capture bait (nanoparticles) were used to harvest TNFα from plasma using 200 µl of particles and 200 µl plasma for each type of nanoparticle. In all cases after treatment with the nanoparticles, TNFα was not detectable in the supernatant by SDS-PAGE with silver staining, whereas TNFα was detectable in the nanoparticle eluate (Figure 1C). (Lane 1 = recombinant TNFα (MW 17,000 Da), Lanes 2 & 3, 4 & 5, 6 & 7 and 8 & 9 represent results for four different types of nanoparticle baits respectively; C = control, S = supernatant, P = nanoparticle eluate).
Dose-response for Different Types of N anoparticles
In order to perform a calibration curve, and thus assess yield and precision, experiments need to be performed with spiked-in proteins of known concentration. Published results for a variety of body fluids and analytes demonstrate how the nanoparticle pre-processing maintains linearity of the assay and establishes a calibration curve while enhancing the effective limit of detection10, 16, 26. We have also published studies of between-laboratory precision using the nanoparticles to conduct multi-reaction monitoring mass spectrometry with enhanced sensitivity27.
To compare IL-17 harvesting efficiency by different types of nanoparticle, recombinant IL-17 (17.5 kDa) was added to plasma samples to which either poly(NIPAm-co-AAc) or poly(NIPAm-co-VSA) nanoparticles were subsequently added. Two sets of four serial dilutions of 100 ng of recombinant IL-17 were prepared in 100 µl plasma (100 ng/100 µl, 50 ng/100 µl, 25 ng/100 µl and 12.5 ng/100 µl). poly(NIPAm-co-AAc) or poly(NIPAm-co-VSA) particles were added to the respective plasma samples in a 1:1 (v/v) particle:plasma ratio. A spectrophotometric total protein assay was performed on the supernatant samples. Western blotting with anti-rabbit polyclonal IL-17 was performed on 20 μg of plasma supernatant (S) after nanoparticle harvesting and the nanoparticle eluates (P) (Figure 4). Both nanoparticle types adequately harvested and concentrated IL-17 at each dilution. The additional bands on the western blot represent human serum albumin and immunoglobulin that cross-react with the secondary antibody. (AAc particles: Lanes 1 & 2 = 1 ng/µl IL-17, Lanes 3 & 4 = 0.50 ng/µl, Lanes 5 & 6 = 0.25 ng/µl, Lanes 7 & 8 = 0.125 ng/µl, Lane 9 = IL-17; VSA particles: Lanes 1 & 2 = 1 ng/µl IL-17, Lanes 3 & 4 = 0.50 ng/µl, Lanes 5 & 6 = 0.25 ng/µl, Lanes 7 & 8 = 0.125 ng/µl).
Detection of Potentially Diagnostic Proteins in Urine
Human urine samples, obtained from healthy volunteer donors with written informed consent, were spiked with a recombinant Mycobacterium species antigen Early Secretory Target Mycobacterium Tuberculosis protein (ESAT-6) to mimic Mycobacterium tuberculosis infected individuals. 1 µg each of ESAT-6 (15 kDa) and IL-2 (15.5 kDa) were added to 1 ml aliquots of human urine collected from healthy volunteer donors. Urinalysis was performed on the samples with a urine reagent strip to determine the optimal ratio of nanoparticles to urine, which was based on the presence/absence of urinary proteins. Poly(NIPAm/dye) nanoparticles were used to harvest proteins from treated and untreated urine samples. One-dimensional gel electrophoresis of the nanoparticle eluates was performed followed by silver staining. Samples in U4 and U6 lanes represent nanoparticle eluates from ESAT-6 and IL-2 treated urine samples, clearly showing prominent bands at 15 kDa (Figure 5). Mass spectrometry of the eluates identified ESAT-6 (UniProt accession POA567, 84.0 coverage, 9 peptides) and IL-2 (UniProt accession P60568, 38.56 coverage, 3 peptides). Urine without nanoparticle harvesting is shown in the lane labeled “Raw”.
Figure 1. Nanoparticles harvest and concentrate low abundance proteins from complex biological fluids. (A) Workflow for harvesting proteins. Total processing time is approximately 1.5 hr. Proteins in solution are concentrated from blood, serum, plasma, urine, sweat, saliva, or other body fluids (1,000-fold concentration depicted). (B) Batch to batch comparison showing the uniform size of nanoparticles. Atomic Force Microscopy on mica shows uniformity of size (0.7 µm diameter) and absence of clumping in two batches of nanoparticles. (C) 1-D gel electrophoresis, with subsequent silver staining, of Tumor Necrosis Factor alpha (TNFα) sequestered from plasma. Please click here to view a larger version of this figure.
Figure 2. Nanoparticle harvesting procedure from plasma/serum for downstream mass spectrometry analysis. (A) Nanoparticles remain suspended in solution (Poly(NIPAm/dye) shown). (B) Nanoparticles are added to the diluted plasma sample. (C) The nanoparticle-plasma suspension is spun in a centrifuge to separate the nanoparticles from the supernatant. (D) Post centrifugation, the nanoparticles form a distinct pellet in the bottom of the tube. (E) After washing the nanoparticles, the eluate containing the harvested proteins is removed and saved for downstream analysis. (F) The eluate is dried under nitrogen flow in an evaporator at 42.1 °C, air flow 8, for 1 – 2 hr prior to mass spectrometry. Please click here to view a larger version of this figure.
Figure 3. Urinalysis using multi-analyte reagent strips for specimen quality control. (A) Each pad on the reagent strip is impregnated with chemicals, enzymes, and/or indicator dyes which react with a different urine analyte (e.g., glucose, bilirubin, ketone, specific gravity, blood, pH, protein, urobilinogen, nitrite, and/or leukocyte esterase). Urine is clarified by centrifugation. A drop of urine is added to each pad on the reagent strip. (B) The color of each pad is compared visually to the color blocks on the container, at the specified time. Please click here to view a larger version of this figure.
Figure 4. Harvesting IL-17 from plasma using core (AAc) or core-shell (VSA) nanoparticles. 1-D gel electrophoresis and western blotting with anti-IL-17 demonstrates the ability of Acrylic Acid (AAc) and VSA core shell nanoparticles to harvest various concentrations of IL-17 from plasma. (S = supernatant after nanoparticle harvesting, P = nanoparticle eluate. AAc particles: Lanes 1 & 2 = 1 ng/µl IL-17, Lanes 3 & 4 = 0.50 ng/µl, Lanes 5 & 6 = 0.25ng/µl, Lanes 7 & 8 = 0.125 ng/µl, Lane 9 = IL-17; VSA particles: Lanes 1 & 2 = 1 ng/µl IL-17, Lanes 3 & 4 = 0.50 ng/µl, Lanes 5 & 6 = 0.25 ng/µl, Lanes 7 & 8 = 0.125 ng/µl) Please click here to view a larger version of this figure.
Figure 5. Recovery of Mycobacterium tuberculosis antigen and cytokine IL-2 from urine using hydrogel nanoparticles. Silver staining following 1-D gel electrophoresis of urine samples. Samples in lanes U4 and U6 represent eluates from urine samples containing recombinant ESAT-6 and IL-2, clearly showing prominent bands at 15 kDa. Mass spectrometry of the eluates identified ESAT-6 (UniProt accession POA567, 84.0 coverage, 9 peptides) and IL-2 (UniProt accession P60568, 38.56 coverage, 3 peptides). (RAW=urine without nanoparticle harvesting; U1, U2, U3, U5, U7, U8 = urine lacking recombinant ESAT-6 and IL-2 following nanoparticle harvesting). Please click here to view a larger version of this figure.
Protein name | GI protein number | Concentration in serum / plasma [ng/ml] | Reference |
abl-interactor 1 isoform a | 61743942 | Unknown | |
AMP-activated protein kinase gamma2 subunit isoform a | 33186925 | Unknown | |
Cas-Br-M (murine) ecotropic retroviral transforming sequence | 52426745 | Unknown | |
chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) | 4506831 | 30 | 34 |
chemokine (C-C motif) ligand 5 | 22538814 | 1.5 | 31 |
chondroadherin | 153251229 | Unknown | |
chromosome 16 open reading frame 80 | 8392875 | Unknown | |
Consortin | 213021160 | Unknown | |
defensin, alpha 4, corticostatin | 4503303 | Unknown | |
EF-hand domain family, member D2 | 20149675 | Unknown | |
glycoprotein Ib (platelet), beta polypeptide | 4504073 | Unknown | |
guanine nucleotide binding protein (G protein), q polypeptide | 40254462 | Unknown | |
Heparanase | 148746204 | Unknown | |
insulin-like growth factor 2 (somatomedin A) | 189083846 | 100 | 30 |
lacritin | 15187164 | Unknown | |
leukocyte cell-derived chemotaxin 2 | 59806345 | 200,000 | 33 |
lipocalin 2 (oncogene 24p3) | 38455402 | 0.05 | 28 |
Monoglyceride lipase, isoform CRA_b | 6005786 | Unknown | |
N-ethylmaleimide-sensitive factor attachment protein, alpha | 47933379 | Unknown | |
one cut homeobox 2 | 119220564 | Unknown | |
outer dense fiber of sperm tails 4 | 171184433 | Unknown | |
palate, lung and nasal epithelium associated | 18765705 | Unknown | |
peptidoglycan recognition protein 2 | 156616294 | Unknown | |
platelet-derived growth factor alpha polypeptide | 77695917 | 4 | 29 |
Protein CASC3 | 15721939 | Unknown | |
RAB27B, member RAS oncogene family | 5729997 | Unknown | |
Ras association (RalGDS/AF-6) domain family 6 isoform a | 29789443 | Unknown | |
ras-related GTP-binding protein RAB10 | 33695095 | Unknown | |
ring finger protein 166 | 30520320 | Unknown | |
serum deprivation response (phosphatidylserine binding protein) | 4759082 | Unknown | |
solute carrier family 33 (acetyl-CoA transporter), member 1 | 4757708 | Unknown | |
ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 isoform a | 27765091 | 15 | 32 |
thymosin-like 3 | 34013530 | Unknown | |
transducin-like enhancer of split 3 (E(sp135) homolog, Drosophila) | 157384982 | Unknown | |
transglutaminase 1 | 4507475 | Unknown | |
WD repeat domain 1 | 9257257 | Unknown | |
WD repeat domain 91 | 222080092 | Unknown | |
xin actin-binding repeat containing 2 | 119372317 | Unknown |
Table 1. Example low abundance proteins harvested by nanoparticles from serum/plasma. (PeptideAtlas peptidome mass spectrometry)28-34. Adapted with permissionfrom reference 13(Tamburro, D. et al.Multi-functional core-shell nanoparticles: Discovery of previously invisible biomarkers. J Am Chem Soc, 133, 19178-19188, (2011).) Copyright 2011 American Chemical Society.
Clinical Relevance
A serum or plasma sample is thought to contain low-abundance circulating proteins and peptides which can provide a rich source of information regarding the state of the organism as a whole. Despite the promise of serum proteomics, there are three fundamental and serious physiologic barriers thwarting biomarker discovery and translation to clinical benefit10, 11, 16, 25.
1. Important diagnostic biomarkers may exist in extremely low-abundance (concentration) in blood. Early stage diseased tissue, such as pre-metastatic cancer lesions, may constitute less than a few mm3. Biomarkers shed into the circulation from such a small tissue volume will become highly diluted in the entire blood volume. Relevant analytes may exist below the detection limits of mass spectrometry and conventional immunoassays.
2. Low abundance biomarkers/proteins are masked by the presence of high abundant proteins such as albumin and immunoglobulin, which represent up to 90% of the plasma proteome14.
3. Proteins and peptides are susceptible to degradation by endogenous and exogenous proteinases following venipuncture and sample transport/storage. Protein degradation can lead to false positive or false negative results35.
Hydrogel nanoparticles were developed as porous, buoyant, polymers containing anthraquinonetriazine dyes and/or vinylsulfonic acid shells for protein and peptide harvesting and preservation in body fluids11, 13. Our group synthesized and tested hydrogel nanoparticles functionalized with a plethora of organic dyes (i.e., sulfonated and non-sulfonatedanthraquinonetriazine dyes) and showed the preferential affinities for several protein analytes11, 13. We also established protocols for biomarker discovery that use hydrogel nanoparticles with lymph, saliva, cerebrospinal fluid, sweat, urine, plasma, blood, or serum specimens11, 13, 23, 24, 26.
Optimizing the nanoparticle harvesting parameters prior to harvesting proteins from precious clinical/research specimens is necessary for ideal results. The amount of protein in the samples should be quantified to determine the optimum ratio of nanoparticles to sample volume. For analytes of unknown concentration, a dose-response curve using recombinant proteins provides information regarding the limits of detection. If there is adequate sample, various types of nanoparticles can be used to determine the ideal nanoparticle for the analyte and specimen.
Urinalysis prior to nanoparticle harvesting provides a urine sample quality control check. The affinity of the nanoparticle dye bait depends on the isoelectric point of the protein of interest and the pH of the surrounding medium. Urine pH between 5.5 and 7.0 is optimal for protein harvesting with the poly(NIPAm/dye) nanoparticles. The presence of hemolyzed or intact red blood cells (1+ blood on the reagent strip) does not interfere with nanoparticle harvesting.
In this protocol we focused on the application of the hydrogel nanoparticles to harvest proteins from plasma and urine. Future applications could comprise other body fluids such as vitreous of the eye, or synovial fluid. Potential in vivo applications can be envisioned for the future in which nanoparticles are injected into diseased tissue to collect biomolecules. Future work will also be focused on the development of new devices for the capture and preservation of biomarkers, such as a nanoparticle-based skin patch for the analysis of the skin transudate proteome.
The authors have nothing to disclose.
Michael Henry, Dublin City University, kindly assisted with the data collection and analysis shown in Figure 5. This work was supported partially by (1) George Mason University, (2) the Italian IstitutoSuperiore di Sanita’ in the framework of the Italy/USA cooperation agreement between the U.S. Department of Health and Human Services, George Mason University, and the Italian Ministry of Public Health, (3) NIH, IMAT program grants 1R21CA137706-01 and 1R33CA173359-01 to LAL, and (4) Ceres Nanosciences, Inc.
hydrogel nanoparticles | Ceres Nanoscience | CS003 | NanoTrap ESP particles |
18 MΩ-cm water | Type 1 reagent grade water | ||
Tris HCl, 50mM pH7.0 | VWR | IC816116 | 50mM, pH 7 |
Acetonitrile | BDH | BDH1103-4LP | available from VWR |
Ammonium Hydroxide NH4OH | BDH | BDH3014 | available from VWR, assayed at 28-30% NH3 |
sodium thiocyanate 25mM | Acros Organics | 419675000 | for serum/plasma samples |
Multi-analyte Urine Reagent Strips | Siemens | 2161 | for urine samples |
Tris-Glycine SDS Sample Buffer (2X) | Life Technologies | LC2676 | use at room temperature to prevent SDS from precipitating |
Dry bath incubator (100 oC) with heating block | Barnstead | 11-715-125DQ | do not substitute a boiling water bath |
Nitrogen evaporator manifold | Organomation Associates | Microvap118 | for serum/plasma samples |
Centrifuge, swing-out rotor | Sorvall | Legend series | 50ml tube capacity, rcf 3700 x g |
Centrifuge, fixed angle rotor | Eppendorf | 5424 | 1.7ml microcentrifuge capacity, rcf 16,000 x g |
50ml conical centrifuge tubes | Fisher Scientific | 14-432-22 | with screw caps for urine samples |
1.5ml microcentrifuge tubes | Eppendorf | 22363204 | |
Disposable plastic transfer pipettes | Fisher Scientific | 13-711-7M | at least 1ml capacity |
Vortex mixer | Fisher Scientific | 50-949-755 | |
Timer | Fisher Scientific | S04782 | seconds/minutes |